The present invention relates to the Chimeric antigen receptors with what in conjunction with target antigen. The Chimeric antigen receptor includes that at least one contains the antigentic specificity targeting district developed from wild-type antibodies or the multi-specificity antibody of its segment, and the antigentic specificity targeting district has at least one of following characteristic: (a) activity declines with wild-type antibodies or its segment compared in the measurement under normal physiological conditions, and (b) in measurement in exception conditions compared with wild-type antibodies or its segment increased activity. Additionally provide the method using Chimeric antigen receptor and cytotoxic cell what treatment of cancer.本發明涉及用於與靶抗原結合的嵌合抗原受體。該嵌合抗原受體包含至少一個含有演變自野生型抗體或其片段的多特異性抗體的抗原特異性靶向區，並且該抗原特異性靶向區具有以下特性中的至少一種：(a)在正常生理條件下的測定中與野生型抗體或其片段相比活性下降，以及(b)在異常條件下的測定中與野生型抗體或其片段相比活性增强。還提供了使用嵌合抗原受體和細胞毒性細胞用於癌症治療的方法。
